Home / Market News / $MRNA
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

Morgan Stanley Adjusts Price Target on Moderna to $200 From $95

Nov 17, 2026, 11:35 AM UTC · Primary ticker $MRNA

Morgan Stanley significantly increased its price target for Moderna, more than doubling it from $95 to $200. This indicates a substantially more bullish outlook from a major investment bank, likely driven by new information or revised assumptions about Moderna's future prospects, which could positively influence investor sentiment and stock price.

Morgan Stanley has updated its financial outlook for Moderna, Inc., raising its price target from $95 to $200. This is a significant upward revision, suggesting a strong positive re-evaluation of Moderna's valuation by a prominent investment bank. This news is primarily positive for Moderna as it signals increased confidence from a major financial institution, potentially attracting more investors and driving up the stock price in the short term. For traders, this presents an opportunity to capitalize on potential upward momentum, though the long-term implications depend on the underlying reasons for Morgan Stanley's revised outlook and Moderna's actual performance. The key risk is that the market may have already priced in such an upgrade, or that the upgrade is based on assumptions that may not materialize.

$MRNA positive Price target raised by Morgan Stanley
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.